Bullock D Fraser 4
4 · Health Catalyst, Inc. · Filed Jul 29, 2019
Insider Transaction Report
Form 4
Bullock D Fraser
Director
Transactions
- Conversion
Common Stock
2019-07-29+345,591→ 982,371 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2019-07-29−636,780→ 0 total(indirect: See footnote)→ Common Stock (636,780 underlying) - Conversion
Series D Preferred Stock
2019-07-29−235,916→ 0 total(indirect: See footnote)→ Common Stock (235,916 underlying) - Conversion
Common Stock
2019-07-29+636,780→ 636,780 total(indirect: See Footnote) - Conversion
Common Stock
2019-07-29+235,916→ 1,218,287 total(indirect: See Footnote) - Conversion
Series C Preferred Stock
2019-07-29−345,591→ 0 total(indirect: See footnote)→ Common Stock (345,591 underlying)
Footnotes (4)
- [F1]Each share of Series B Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.
- [F2]These shares are held directly by HQC Acquisition, LLC. The Reporting Person is the President of HQC Acquisition, LLC and it is controlled by Sorenson Capital Partners. The Reporting Person is a founding member and general partner of Sorenson Capital Partners and disclaims beneficial ownership of the shares held by HQC Acquisition, LLC except to the extent of his pecuniary interest therein.
- [F3]Each share of Series C Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.
- [F4]Each share of Series D Preferred Stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a one-for-one basis, and had no expiration date.